News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing HSA growth and the opportunities emerging for investors and ... Paying attention to the intersection of public policy and business opportunity can be a winning strategy for start-ups and disrupters.
Market Access Why the NHS remains the world's most challenging – and rewar... For pharmaceutical, biotech, and medtech companies eyeing global expansion, the NHS presents a paradox.
News Medicxi raises €500m for latest biotech fund Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+.
News Lilly reveals $3bn orforglipron facility in Netherlands After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.
News AZ starts work on Virginia plant in $50bn US investment plan The first stage of AstraZeneca's promised $50 billion investment in US facilities is underway as it breaks ground on a facility in Virginia.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
